Laboratorios Grin, founded in 1955, is a Mexican company dedicated to enhancing health through innovations in ophthalmological products, antibiotics, and antivertiginous medications. With a commitment to high-quality standards, the company has positioned itself as a significant player in the healthcare sector in both Mexico and Latin America.
In 2014, Laboratorios Grin expanded its capabilities and reach by aligning with Lupin Group Company, a global leader in pharmaceuticals. This strategic partnership enables the company to further its product development, production processes, and business model, aiming to serve over 2.3 million individuals with visual health conditions in the region.
Despite its long history and strategic partnerships, Laboratorios Grin has not disclosed recent investment activities or investor details, suggesting potential opportunities for new investor involvement to leverage its established market presence and innovative potential in the biotechnology and pharmaceutical industries.
